Literature DB >> 30980688

Management of Hepatitis C Infection in children in the era of Direct-acting Antiviral Agents.

Wikrom Karnsakul1, Kathleen B Schwarz1.   

Abstract

Chronic hepatitis C certainly is a global health burden in children as well as in adults. Spontaneous viral clearance can occur in early childhood but is uncommon thereafter. Although the majority of cases are asymptomatic during childhood and young adulthood, without an effective treatment, children who acquire HCV via vertical transmission can develop chronic liver disease and other complications including end-stage liver disease and hepatocellular carcinoma in adulthood. Efforts from worldwide health organizations, the pharmaceutical industry, and clinical and research institutions have resulted in very effective interferon-free therapy with direct-acting antiviral agents (DAAs) for HCV-infected children. In this manuscript, we will briefly review the epidemiology of HCV in children, historic treatment, current published data on DAAs in children and conclude with suggestions for management of the child with HCV in the era of DAAs.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  DAAs; daclatasvir in children; direct-acting antiviral agents; hepatitis C; ledipasvir; sofosbuvir; sofosbuvir in children

Year:  2019        PMID: 30980688     DOI: 10.1111/jvh.13113

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  3 in total

1.  Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments.

Authors:  Rosalia Ragusa; Liberato Simone Corsaro; Evelise Frazzetto; Emanuele Bertino; Maria Alessandra Bellia; Gaetano Bertino
Journal:  AJP Rep       Date:  2020-03-31

2.  Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines.

Authors:  Farihah Malik; Heather Bailey; Polin Chan; Intira Jeannie Collins; Antons Mozalevskis; Claire Thorne; Philippa Easterbrook
Journal:  JHEP Rep       Date:  2021-01-15

3.  Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities-A Brief Report.

Authors:  Maria Pokorska-Śpiewak; Anna Dobrzeniecka; Agnieszka Ogrodnik
Journal:  Infect Dis Rep       Date:  2022-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.